---
title: "Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity"
date: 2025-08-27T18:54:22.867Z
source: "finance.yahoo.com"
source_url: https://finance.yahoo.com/news/lillys-oral-glp-1-orforglipron-104500826.html
---

## Shrnutí (CZ)
Oops, something went wrong

We are experiencing some temporary issues. The market data on this page is currently delayed. In ATTAIN-2, orforglipron met the primary and all key secondary endpoints, with compelling efficacy results and a safety profile consistent with injectable GLP-1 medicines

Participants with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost an average of 22.

---

[Otevřít zdroj](https://finance.yahoo.com/news/lillys-oral-glp-1-orforglipron-104500826.html)
